Søgeord (covid-19) valgt.
839 emner vises.
1
COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes - National Healthcare Safety Network, United States, October 2023-February 2024
Morbidity and Mortality Weekly Report (MMWR), 19.04.2024
Tilføjet 19.04.2024
This report describes COVID-19 rates, hospitalizations, and vaccination coverage among nursing home residents.
Læs mere
2
Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023
Morbidity and Mortality Weekly Report (MMWR), 19.04.2024
Tilføjet 19.04.2024
This report describes the duration of protection provided by the original monovalent COVID-19 vaccines.
Læs mere
3
Surveillance of COVID-19 in long-term care facilities in the EU/EEA 2021-2023
ECDC
ECDC COVID-19 updates, 17.04.2024
Tilføjet 17.04.2024
This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
Læs mere
4
COVID Vaccinations Less Prevalent in Marginalized Patients
Medscape Infectious Diseases, 15.04.2024
Tilføjet 15.04.2024
Primary care doctors who serve marginalized communities had the highest rate of patients unvaccinated against COVID-19 in a recent study. Medscape Medical News
Læs mere
5
Communicable disease threats report, 7 - 13 April 2024, week 15
ECDC
ECDC COVID-19 updates, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mere
6
Communicable disease threats report, 7 - 13 April 2024, week 15
ECDC
ECDC Communicable Disease Threats Report, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mere
7
Excess mortality in Europe coincides with peaks of COVID-19, influenza and respiratory syncytial virus (RSV), November 2023 to February 2024
Sarah K Nørgaard, Jens Nielsen, Anne Christine Nordholm, Lukas Richter, Alena Chalupka, Natalia Bustos Sierra, Toon Braeye, Maria Athanasiadou, Theodore Lytras, Gleb Denissov, Oskari Luomala, Anne Fouillet, Isabelle Pontais, Matthias an der Heiden, Benedikt Zacher, Alina Weigel, Ivo Foppa, Kassiani Gkolfinopoulou, Ioannis Panagoulias, Anna Paldy, Tibor Malnasi, Lisa Domegan, Eva Kelly, Naama Rotem, Oksana Rakhlin, Francesca K de'Donato, Chiara Di Blasi, Patrick Hoffmann, Telma Velez, Kathleen England, Neville Calleja, Liselotte van Asten, Femke Jongenotter, Ana Paula Rodrigues, Susana Silva, Petra Klepac, Diana Gomez-Barroso, Inmaculada Leon Gomez, Ilias Galanis, Ahmed Farah, Rolf Weitkunat, Katarina Fehst, Nick Andrews, Tom Clare, Declan T Bradley, Mark G O'Doherty, Naoma William, Mark Hamilton, Bolette Søborg, Tyra G Krause, Nick Bundle and Lasse S Vestergaard
Eurosurveillance latest updates, 12.04.2024
Tilføjet 12.04.2024
Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.
Læs mere
8
Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine - Oregon, June 2021-December 2022
Morbidity and Mortality Weekly Report (MMWR), 12.04.2024
Tilføjet 12.04.2024
This report describes a review of Oregon death certificate data to assess whether young people in Oregon might be dying after receiving a COVID-19 vaccine.
Læs mere
9
COVID-19 Vaccination Coverage - World Health Organization African Region, 2021-2023
Morbidity and Mortality Weekly Report (MMWR), 12.04.2024
Tilføjet 12.04.2024
This report describes COVID-19 vaccination coverage in the World Health Organization African Region during 2021-2023.
Læs mere
10
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation due to COVID-19 and death using electronic health records in eight European countries: first update
ECDC
ECDC COVID-19 updates, 8.04.2024
Tilføjet 8.04.2024
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Læs mere
11
The approach to developing Ireland’s first national health protection strategy and lessons learnt, December 2021 to October 2022
Ciara Kelly, Joan Gallagher, Lola Odewumi, Robert Conway, Mary E Black, Kristin Concannon, Louise Marron and Lorraine Doherty
Eurosurveillance latest updates, 5.04.2024
Tilføjet 5.04.2024
The COVID-19 pandemic highlighted the importance of strengthening health protection worldwide. To address this as a public health priority in Ireland, between December 2021 and October 2022 the first national Health Protection Strategy (2022–2027) for the Irish Health Service Executive (HSE) was developed. We describe the approach taken to develop a first national health protection strategy for Ireland, and highlight the key lessons learned. Key steps in strategy formation included detailed stakeholder analysis, exploration of the context for the strategy and development of a comprehensive consultation plan. Two stakeholder consultation workshops were held. The first focused on defining strategic vision, aim and objectives, the second verified objectives and identified enablers. A subsequent e-consultation invited feedback from wider stakeholders. The published strategy outlines 10 strategic objectives and 11 enablers. Key lessons identified from the strategy development process include the importance of clear leadership and oversight, the value of identifying the context for change, ensuring adequate consultation planning, taking a multidisciplinary approach with strong stakeholder engagement and the need to maintain a strategic perspective. Lessons from our experience can support colleagues internationally to strategically set out their priorities for health protection beyond COVID-19.
Læs mere
12
Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics - United States, September 1, 2022-September 30, 2023
Morbidity and Mortality Weekly Report (MMWR), 5.04.2024
Tilføjet 5.04.2024
This report describes the number of COVID-19 bivalent vaccine doses administered by Federal Retail Pharmacy Program partners.
Læs mere
13
Paxlovid Not Effective for COVID-19 Symptom Relief
Medscape Infectious Diseases, 5.04.2024
Tilføjet 5.04.2024
Clinicians should still consider prescribing the drug to adults over age 65 or those who are immunocompromised, experts said. Medscape Medical News
Læs mere
14
The ED Sailed Smoothly in the Early COVID-19 Days
Medscape Infectious Diseases, 1.04.2024
Tilføjet 1.04.2024
The findings of this study, which focused on the early phases of the COVID-19 pandemic, may be useful to administrators and policymakers in case of a future pandemic outbreak. Medscape Medical News
Læs mere
15
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mere
16
Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Germany, 2021 to 2023
Wei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Ekkehard Schuler, Barbara Biere, Brunhilde Schweiger, Luise Goerlitz, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundNon-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. AimTo describe, for children aged
Læs mere
17
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024
Morbidity and Mortality Weekly Report (MMWR), 29.03.2024
Tilføjet 29.03.2024
This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.
Læs mere
18
No Increased Stroke Risk After COVID-19 Bivalent Vaccine
Medscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
There is no increased risk for stroke during the 6 weeks following receipt of either brand of the COVID-19 bivalent vaccine, new research shows. Medscape Medical News
Læs mere
19
How COVID-19 Treatments Affect Patients With IBD
Medscape Infectious Diseases, 26.03.2024
Tilføjet 26.03.2024
Inflammatory bowel disease therapies for patients may need to be briefly halted during treatment for COVID-19, but it does not increase flares. Medscape Medical News
Læs mere
20
Severe Flu Confers Higher Risk for Neuro Disorders vs COVID
Medscape Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Hospitalization for influenza raises the risk for future neurologic conditions more than hospitalization for COVID-19, the results of a large study showed. Medscape Medical News
Læs mere
21
Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis During the COVID-19 Pandemic - United States, 2019-2021
Morbidity and Mortality Weekly Report (MMWR), 21.03.2024
Tilføjet 21.03.2024
This report describes trends in coccidioidomycosis, histoplasmosis, and blastomycosis cases during the COVID-19 pandemic.
Læs mere
22
Immunomodulators Do Not Affect COVID-19 Vaccine Efficacy
Medscape Infectious Diseases, 21.03.2024
Tilføjet 21.03.2024
A study suggested that immunomodulatory medications do not increase the risk for COVID-19 related hospitalizations in patients who have received the COVID-19 vaccine. Medscape Medical News
Læs mere
23
'Critical' to Catch Up on Measles Vaccinations to Stem Outbreaks, Says WHO
Medscape Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
Vaccinating children who missed their measles shots during the COVID-19 pandemic is critical, a senior World Health Organization official said on Tuesday, as outbreaks of... Reuters Health Information
Læs mere
24
After-Action review of the public health response of Slovenia to the COVID-19 pandemic
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.
Læs mere
25
Reporting Protocol for integrated respiratory virus surveillance, version 1.5
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
26
Epilepsy Linked to Higher COVID Hospitalization, Death Rates
Medscape Infectious Diseases, 15.03.2024
Tilføjet 15.03.2024
Epilepsy was linked to a significantly increased the risk for hospitalization and death from COVID-19 early in the pandemic, while healthcare utilization rates declined. Medscape Medical News
Læs mere
27
Protocol for a COVID-19 vaccine effectiveness multi-country cohort study in the paediatric population aged 5–17-years using electronic health records in EU/EEA countries
ECDC
ECDC COVID-19 updates, 15.03.2024
Tilføjet 15.03.2024
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.
Læs mere
28
Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children - United States, 2023
Morbidity and Mortality Weekly Report (MMWR), 14.03.2024
Tilføjet 14.03.2024
This report describes changes in multisystem inflammatory syndrome cases among children since early in the COVID-19 pandemic.
Læs mere
29
Projecting COVID-19 intensive care admissions for policy advice, the Netherlands, February 2020 to January 2021
Don Klinkenberg, Jantien Backer, Nicolette de Keizer and Jacco Wallinga
Eurosurveillance latest updates, 8.03.2024
Tilføjet 8.03.2024
BackgroundModel projections of coronavirus disease 2019 (COVID-19) incidence help policymakers about decisions to implement or lift control measures. During the pandemic, policymakers in the Netherlands were informed on a weekly basis with short-term projections of COVID-19 intensive care unit (ICU) admissions. AimWe aimed at developing a model on ICU admissions and updating a procedure for informing policymakers. MethodThe projections were produced using an age-structured transmission model. A consistent, incremental update procedure integrating all new surveillance and hospital data was conducted weekly. First, up-to-date estimates for most parameter values were obtained through re-analysis of all data sources. Then, estimates were made for changes in the age-specific contact rates in response to policy changes. Finally, a piecewise constant transmission rate was estimated by fitting the model to reported daily ICU admissions, with a changepoint analysis guided by Akaike\'s Information Criterion. ResultsThe model and update procedure allowed us to make weekly projections. Most 3-week prediction intervals were accurate in covering the later observed numbers of ICU admissions. When projections were too high in March and August 2020 or too low in November 2020, the estimated effectiveness of the policy changes was adequately adapted in the changepoint analysis based on the natural accumulation of incoming data. ConclusionThe model incorporates basic epidemiological principles and most model parameters were estimated per data source. Therefore, it had potential to be adapted to a more complex epidemiological situation with the rise of new variants and the start of vaccination.
Læs mere
30
Risk for Rheumatic Disease May Rise After COVID
Medscape Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
While previous studies had identified a link between COVID-19 infection and greater risk for autoimmune disease, a new study is perhaps the largest and most robust to date to show an association. MDedge News
Læs mere
31
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 29.02.2024
Tilføjet 29.02.2024
This report describes vaccine effectiveness for the updated 2023-24 COVID-19 vaccine.
Læs mere
32
Cognitive Deficits Post-COVID Range From 3-9 IQ Point Loss
Medscape Infectious Diseases, 29.02.2024
Tilføjet 29.02.2024
COVID-19–related cognitive deficits in severe cases were equivalent to a 9-point drop in IQ, new data show, with most deficits in memory, reasoning, and executive function. Medscape Medical News
Læs mere
33
Studie med 99 mio. deltagere: Alvorlige bivirkninger efter covid-19 vacciner er sjældne
Statens Serum Institut, 23.02.2024
Tilføjet 23.02.2024
Verdens største studie af covid-19 vaccinernes sikkerhed bekræfter, at alvorlige bivirkninger efter vaccination sjældne.
Læs mere
34
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany’s experience during the COVID-19 pandemic, July 2021 to March 2023
Nita Perumal, Viktoria Schönfeld and Ole Wichmann
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country’s overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.
Læs mere
35
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
Shogo Miyazawa, Ting Sam Wong, Genta Ito, Ryo Iwamoto, Kozo Watanabe, Michiel van Boven, Jacco Wallinga and Fuminari Miura
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWastewater surveillance has expanded globally as a means to monitor spread of infectious diseases. An inherent challenge is substantial noise and bias in wastewater data because of the sampling and quantification process, limiting the applicability of wastewater surveillance as a monitoring tool. AimTo present an analytical framework for capturing the growth trend of circulating infections from wastewater data and conducting scenario analyses to guide policy decisions. MethodsWe developed a mathematical model for translating the observed SARS-CoV-2 viral load in wastewater into effective reproduction numbers. We used an extended Kalman filter to infer underlying transmissions by smoothing out observational noise. We also illustrated the impact of different countermeasures such as expanded vaccinations and non-pharmaceutical interventions on the projected number of cases using three study areas in Japan during 2021–22 as an example. ResultsObserved notified cases were matched with the range of cases estimated by our approach with wastewater data only, across different study areas and virus quantification methods, especially when the disease prevalence was high. Estimated reproduction numbers derived from wastewater data were consistent with notification-based reproduction numbers. Our projections showed that a 10–20% increase in vaccination coverage or a 10% reduction in contact rate may suffice to initiate a declining trend in study areas. ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.
Læs mere
36
Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024
Morbidity and Mortality Weekly Report (MMWR), 22.02.2024
Tilføjet 22.02.2024
This report describes an increase in Mycoplasma pneumoniae, a common cause of respiratory illness, beginning in fall 2023.
Læs mere
37
Italy Spent Around 45% Of EU COVID Recovery Cash Received So Far, Report Shows
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
Italy has spent around 45% of the almost 102 billion euros ($110.7 billion) it has received so far from European Union COVID-19 recovery funds, short of a target set in... Reuters Health Information
Læs mere
38
Covid-19-smitte giver flere neurologiske diagnoser
Statens Serum Institut, 22.02.2024
Tilføjet 22.02.2024
I den brede danske befolkning blev der diagnosticeret flere neurologiske lidelser efter smitte med covid-19. Det viser en ny stor undersøgelse fra Statens Serum Institut, hvor der indgik knap 1,8 mio smittede danskere.
Læs mere
39
What to Know About COVID Rebound
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
The CDC\'s Pragna Patel, MD, MPH, and Dallas Smith, PharmD, answer common questions on COVID-19 rebound cases and antiviral treatment. CDC Expert Commentary
Læs mere
40
Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation
Christian Holm Hansen
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
Many vaccine effectiveness (VE) analyses of severe disease outcomes such as hospitalisation and death include ‘false’ cases that are not actually caused by the infection or disease under study. While the inclusion of such false cases inflate outcome rates in both vaccinated and unvaccinated populations, it is less obvious how they affect estimates of VE. Illustrating the main points through simple examples, this article shows how VE is underestimated when false cases are included as outcomes. Depending how the outcome indicator is defined, estimates of VE against severe disease outcomes, whose definition allows for the inclusion of false cases, will be biased downwards and may in certain circumstances approximate the same level as the VE against infection. The bias is particularly pronounced for vaccines that offer high levels of protection against severe disease outcomes but poor protection against infection. Analysing outcomes that are measured with low sensitivity generally does not cause bias in VE studies; defining outcome indicators that minimise the number of false cases rather than the number of missed cases is preferable in VE studies.
Læs mere
41
Epidemiology of reported cases of leptospirosis in the EU/EEA, 2010 to 2021
Julien Beauté, Francesco Innocenti, Aristos Aristodimou, Michaela Špačková, Caroline Eves, Natalia Kerbo, Ruska Rimhanen-Finne, Mathieu Picardeau, Mirko Faber, Georgios Dougas, Anna Margrét Halldórsdóttir, Sarah Jackson, Viktorija Leitēna, Anne Vergison, Maria Louise Borg, Roan Pijnacker, Małgorzata Sadkowska-Todys, João Vieira Martins, Lavinia Cipriana Rusu, Eva Grilc, Rosa M Estévez-Reboredo, Taina Niskanen and Therese Westrell
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
BackgroundLeptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Humans are infected by exposure to animal urine or urine-contaminated environments. Although disease incidence is lower in Europe compared with tropical regions, there have been reports of an increase in leptospirosis cases since the 2000s in some European countries. AimWe aimed to describe the epidemiology of reported cases of leptospirosis in the European Union/European Economic Area (EU/EEA) during 2010−2021 and to identify potential changes in epidemiological patterns. MethodsWe ran a descriptive analysis of leptospirosis cases reported by EU/EEA countries to the European Centre for Disease Prevention and Control with disease during 2010−2021. We also analysed trends at EU/EEA and national level. ResultsDuring 2010–2021, 23 countries reported 12,180 confirmed leptospirosis cases corresponding to a mean annual notification rate of 0.24 cases per 100,000 population. Five countries (France, Germany, the Netherlands, Portugal and Romania) accounted for 79% of all reported cases. The highest notification rate was observed in Slovenia with 0.82 cases per 100,000 population. Overall, the notification rate increased by 5.0% per year from 2010 to 2021 (95% CI: 1.2–8.8%), although trends differed across countries. ConclusionThe notification rate of leptospirosis at EU/EEA level increased during 2010−2021 despite including the first 2 years of the COVID-19 pandemic and associated changes in population behaviours. Studies at (sub)national level would help broaden the understanding of differences at country-level and specificities in terms of exposure to Leptospira, as well as biases in diagnosis and reporting.
Læs mere
42
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, Inès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).
Læs mere
43
Laboratory Support for influenza and SARS-CoV-2 for Europe: AURORAE
ECDC
ECDC COVID-19 updates, 15.02.2024
Tilføjet 15.02.2024
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
Læs mere
44
SARS-CoV-2 a Possible Trigger for Achalasia
Medscape Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Researchers described cases of rapidly developing achalasia following COVID-19 and confirmed SARS-CoV-2 antigen in esophageal muscle tissue. Medscape Medical News
Læs mere
45
Protocol for a COVID-19 vaccine effectiveness estimation using health data registries, VEBIS multi-country study - Version 2.0
ECDC
ECDC COVID-19 updates, 13.02.2024
Tilføjet 13.02.2024
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
Læs mere
46
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC Communicable Disease Threats Report, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
47
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC COVID-19 updates, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
48
De første covid-19-vacciner gav ikke flere bivirkninger
Statens Serum Institut, 8.02.2024
Tilføjet 8.02.2024
Særligt på sociale medier har der gennem længere tid floreret en myte om, at de første små partier af covid-19 vaccinen ikke havde samme kvalitet som de senere større partier, og at de derfor førte til langt flere bivirkninger. Denne myte punkteres nu i en ny stor undersøgelse fra Statens Serum Institut.
Læs mere
49
Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 3.0
ECDC
ECDC COVID-19 updates, 6.02.2024
Tilføjet 6.02.2024
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
Læs mere
50
Data on COVID-19 vaccination in the EU/EEA
ECDC
ECDC COVID-19 updates, 2.02.2024
Tilføjet 2.02.2024
This downloadable data file contains information on COVID-19 vaccination in the EU/EEA since September 2023.
Læs mere